Wegovy Pill Australia: When Will the Oral GLP-1 Tablet Arrive?
TL;DR
The Wegovy pill (oral semaglutide) is not yet registered for sale in Australia. The US Food and Drug Administration approved it in December 2025, and Novo Nordisk has since applied to the Therapeutic Goods Administration for local approval. A separate oral GLP-1, orforglipron, is also moving through the TGA process. Australians who want a needle-free option now can ask a doctor about off-label Rybelsus or start on an injectable GLP-1 today. Book a telehealth consultation to discuss what suits your situation.
Introduction
Weekly injections such as Ozempic, Mounjaro, and Wegovy have driven most of the conversation around GLP-1 medicines in Australia. For many patients, the needle is still the biggest barrier to starting treatment.
That is changing. Oral GLP-1 tablets have already reached patients overseas, and two competing products are now working their way through Australian regulatory review. The obvious question for local patients is simple: when can Australians swap the injection for a daily tablet?
This guide sets out what an oral GLP-1 is, where the Wegovy pill and orforglipron stand with the TGA, the realistic timeline for Australian access, and what options already exist for patients who do not want to wait. Every figure below links to its primary source.
What Is an Oral GLP-1?
An oral GLP-1 is a tablet version of the same hormone-mimicking medicines previously available only as weekly injections. It slows stomach emptying, reduces appetite, and signals fullness to the brain, working the same way as the injectable form.
Standard GLP-1 medicines are protein-based peptides. Stomach acid normally breaks proteins down before they can be absorbed, which is why they were injected rather than swallowed.
Two different approaches have solved this problem. Novo Nordisk’s oral semaglutide tablet uses an absorption enhancer called SNAC, which protects the active ingredient long enough for a small amount to cross the stomach lining. Eli Lilly’s orforglipron takes a different route: it is a small-molecule drug rather than a protein, so it naturally resists being broken down by stomach acid.
Wegovy Pill vs Orforglipron: What’s the Difference?
The Wegovy pill is an oral form of semaglutide, the same active ingredient as the Wegovy injection. Orforglipron is a chemically different, non-peptide GLP-1 medicine developed by Eli Lilly, the maker of Mounjaro. Both are taken as a daily tablet, and both have shown meaningful weight loss in clinical trials.
The FDA approved the once-daily 25 mg Wegovy tablet in December 2025 on the strength of the OASIS 4 trial, where participants lost a mean of 16.6% of their body weight, and roughly one in three lost 20% or more. The US launch followed in January 2026.
Orforglipron has moved through its own late-stage program. In an earlier Phase 2 obesity trial, participants lost an average of 14.7% of body weight over 36 weeks. The confirmatory Phase 3 ATTAIN-1 trial, published in the New England Journal of Medicine in September 2025, showed a 12.4% average weight loss over 72 weeks at the highest dose in adults with obesity, alongside improvements in cholesterol, triglycerides, blood pressure, and inflammation markers. Eli Lilly has since triggered global regulatory submissions for orforglipron.
| Feature | Wegovy pill (oral semaglutide) | Orforglipron |
|---|---|---|
| Maker | Novo Nordisk | Eli Lilly |
| Drug class | Peptide, protected with an absorption enhancer | Non-peptide, small-molecule |
| Key trial result | 16.6% mean weight loss (OASIS 4) | 12.4% mean weight loss over 72 weeks (ATTAIN-1) |
| US status | FDA approved, December 2025 | Phase 3 complete, regulatory submissions underway |
| Australian status | TGA application submitted | TGA application submitted, January 2026 |
When Will the Wegovy Pill Be Available in Australia?
Novo Nordisk has confirmed it has applied to the TGA to register the Wegovy pill in Australia, though the company has not published an exact submission date. As of the FDA approval in December 2025, the TGA had not yet received the application, and by May 2026 the submission was confirmed to be underway.
Before any prescription medicine reaches Australian pharmacies, it must clear a TGA assessment for safety, quality, and efficacy. In late 2025, a TGA spokesperson told The Nightly that “the TGA has not received an application for the registration of the Wegovy weight loss pill,” and confirmed that submission timing is a business decision for the manufacturer.
By May 2026, that had changed. Novo Nordisk confirmed to Pharma in Focus that it is “working towards making Wegovy pill available in Australia,” alongside news that Eli Lilly had already lodged its own oral GLP-1 application, orforglipron, with the TGA in January 2026.
Neither company has confirmed an Australian launch date. Based on standard TGA evaluation timeframes, a realistic window is sometime in 2027, though this depends entirely on when each application is formally accepted and whether the TGA requests further information along the way. We will update this article as the TGA publishes new status information.
How Does the TGA Approval Process Work?
A standard TGA evaluation for a new prescription medicine targets up to 255 working days from formal acceptance of the application, which in practice often stretches beyond a year once you include preparation time and any requests for extra data. A priority review pathway exists for medicines that treat serious conditions and offer a substantial clinical advance, cutting the target to around 150 working days.
Both timeframes run only while the TGA is actively assessing the file. Any period where the regulator pauses the clock to wait for more information from the sponsor does not count towards the total, which is why real-world approvals frequently take longer than the headline figure suggests.
It is not yet public whether either oral GLP-1 application has been granted priority status in Australia. Given that Australian patients already have TGA-approved injectable options, a standard review is the more likely path unless the sponsor demonstrates a clear clinical advantage that qualifies for the faster track.
A Daily Pill Still Means a Strict Routine
A once-a-day tablet sounds far simpler than a weekly injection, but the Wegovy pill comes with a routine that has to be followed precisely to work. Because stomach acid still destroys most of the dose, only a small fraction of each tablet is actually absorbed.
The approved dosing instructions require patients to:
- Take the tablet first thing in the morning, on a completely empty stomach.
- Swallow it with no more than 120 ml (about half a cup) of plain water.
- Wait at least 30 minutes before eating, drinking anything else, or taking other oral medicines.
Missing this window, or drinking too much water with the tablet, can reduce how much medicine the body absorbs. For patients with unpredictable mornings, shift work, or young children to manage before breakfast, a weekly injection may actually be the more forgiving option.
Can You Access an Oral GLP-1 in Australia Right Now?
Yes, in a limited form. An oral semaglutide tablet already exists in Australia under the brand name Rybelsus, but the TGA has only approved it for managing type 2 diabetes, not weight loss. A doctor can still prescribe it off-label for weight management if they judge it clinically appropriate for you, at full private cost.
Rybelsus works on the same GLP-1 pathway as the Wegovy pill, and its TGA-approved product information confirms the therapeutic effect of reduced body weight, even though weight loss is not the approved indication. Off-label prescribing is a recognised and legal part of Australian medical practice, but it means the medicine is not subsidised and the decision rests entirely with your prescribing doctor after a full clinical assessment.
If needle-free treatment is not essential to you, injectable options that are already TGA registered, such as Wegovy, Mounjaro, and Ozempic, remain available today under medical supervision. Patients who start on an injection can often move to an oral tablet later, once one is registered in Australia and a doctor agrees it is a suitable switch. Our GLP-1 comparison guide breaks down how these options differ.
How to Take the Next Step
Medical weight management is never one-size-fits-all, and that is especially true while Australia’s oral GLP-1 options are still moving through TGA review. Some patients will choose to wait for a tablet. Others will start on a TGA-approved injectable option today, and some will ask their doctor whether off-label Rybelsus fits their situation.
Whichever path suits you, it starts with a proper clinical assessment, not a guess. Holistica Health’s AHPRA-registered doctors review your BMI, health history, and goals over a secure video or phone consultation, from anywhere in Australia.
Complete the two-minute pre-screening checklist and book a $99 initial weight loss consultation to find out what options are genuinely right for you today.
Conclusion
Three things to take away. The Wegovy pill is not yet registered in Australia, and Novo Nordisk’s TGA application was still under review as of mid-2026, with a realistic local launch unlikely before 2027. Orforglipron, Eli Lilly’s rival oral GLP-1, is on a similar track after its own TGA submission in January 2026. And needle-free access already exists in a limited form today through off-label Rybelsus or a future switch from an existing injectable medicine.
If you want clear, personalised answers rather than general guesswork, skip the wait and speak with a doctor. Book a telehealth weight loss consultation with a Holistica Health doctor today, from anywhere in Australia.
This article is general information, not personal medical advice. The Wegovy pill and orforglipron are not currently registered for use in Australia, and Rybelsus is TGA-approved for type 2 diabetes only. All GLP-1 medicines are prescription-only, and a doctor must assess whether any option is clinically suitable for you before prescribing. Speak with your GP or a Holistica Health doctor before making treatment decisions.